


Life Sciences Financing Summary Europe

October 2016

In July 2016, the downward trend in private financing of Biotech (Therapeutics and Diagnostics) companies continued (EUR 45m from EUR 72m in June 2016). Whilst the number of rounds in July was comparable to the number of rounds in June, the average deal size decreased (EUR 15m from EUR 18m in June). August 2016 was an anomaly where no financing rounds took place in Europe. A year-on-year comparison in aggregate financing value reveals an obvious stark difference for August (EUR 0m in 2016 from EUR 78m in 2015). The aggregate financing value for July 2016 was also significantly lower than in July 2015 (EUR 45m in 2016 to 87m in 2015).

The largest private financing round for European Therapeutics and Diagnostics companies in July and August 2016 was the EUR 31m raised in July by InflaRx GmbH, a monoclonal anti-complement discovery and development company based in Germany.

Continue reading below to learn more about the financing highlights of July and August 2016 in the European Life Science industry (including Israel).



Source: Biotechgate.com

The graph contains only financing rounds of private & independent biotech therapeutic and diagnostic companies. Financing amounts and number of rounds from previous months may alter as new information on financing rounds is received and/or new tranches to existing financing rounds are added.



Selected financing highlights: companies raising funds

July 2016

InflaRx GmbH Raises EUR 31m in a Series C to Foster Complement Inhibitor Development

Jena, Germany – InflaRx GmbH, the biopharmaceutical company developing new therapeutics in the terminal complement space, announced on 21 July 2016 that it has raised EUR 31m in a Series C round. The financing was composed of new investors such as Staidson Hongkong Investment Company Ltd as well as other undisclosed international industrial investors and family offices. Proceeds from the round will be used to advance clinical Phase II development of the lead drug candidate IFX-1, a first-in-class monoclonal anti-complement C5a antibody, in various acute and chronic inflammatory indications as well as the preclinical development of the follow-up pipeline molecules.

(Source: press release)

August 2016

Nutrinia Ltd. Announces USD 30m (EUR 26.8m) Series D Financing

Ramat-Gan, Israel & Morristown NJ, USA – Nutrinia Ltd, a company developing a proprietary oral formulation of insulin for intestinal malabsorption in preterm newborns and Short Bowel Syndrome (SBS) in infants, announced on 18 August 2016 the closing of a USD 30m (EUR 26.8m) Series D financing to fund two pivotal trials for registration. TPG Biotech, the life science venture investment arm of leading global alternative asset firm TPG, led the investment, joined by H.I.G. BioHealth Partners and WuXi Healthcare Ventures, as well as existing investors including OrbiMed, Pontifax and others.

Nutrinia Ltd will use the proceeds to initiate two pivotal trials for registration in separate indications related to acceleration of gut maturation and adaptation: intestinal malabsorption in preterm newborns born between 26 and 32 weeks' gestational age, and infants with SBS who are under 12 months old.

(Source: press release)




Selected financing highlights – investors in July, August 2016

The following investors have made investments into European Life Science companies during July and August 2016:

- Agate Medical Investments LP
- Bavarian Growth Fund
- GE Ventures
- Gilde Healthcare Partners
- H.I.G. BioHealth Partners
- INKEF Capital
- LongTec HongTao China Ventures LP
- OrbiMed
- Pontifax Venture Capital
- Staidson Hongkong Investment Company Ltd
- TPG Biotech
- Wolf Biotech GmbH
- VRD GmbH
- WuXi Healthcare Ventures

Quarterly biotech equity financing breakdown by investment size (Therapeutics and Diagnostics)

In the second quarter of 2016, 41% of the financing rounds of Biotech companies (Therapeutics and Diagnostics) were in the smallest investment segment, those less than EUR 5m. This represents a significant decrease compared to the first quarter of 2016 (41% from 54% in Q1 2016). The second most frequent investment size in the second quarter was the EUR 5m to EUR 15m segment, accounting for 29% of all financing rounds. Compared to the first quarter of 2016, particularly the EUR 30m to EUR 50m segment gained relative importance. As one can see in the graph below, the largest investment segment was not represented in Q2 2016, down from 4% in the previous quarter.



The graph above shows the proportion of financing rounds by investment size in the therapeutics and diagnostics category per quarter, including only private companies.

July, August 2016 financing rounds summary

Company Name	Sector	Amount (in Million EUR)	Ownership	Country
Nutrinia Ltd.	Biotechnology - Therapeutics and Diagnostics	26.8	Private / independent	Israel
ProteoMediX AG	Biotechnology / R&D Services	4.6	Private / independent	Switzerland
MAZOR Robotics Ltd	Medical Technology	17.9	Publicly listed on stock exchange	Israel
Medicrea International SA	Medical Technology	17.9	Publicly listed on stock exchange	France
AB-Biotics SA	Biotechnology - other	5.0	Publicly listed on stock exchange	Spain
Leanbio	Biotechnology - other	0.2	Private / independent	Spain
Ornim Medical Ltd.	Medical Technology	17.9	Private / independent	Israel
Bioprognos	Biotechnology / R&D Services	0.4	Private / independent	Spain
Biophytis	Biotechnology - Therapeutics and Diagnostics	1.0	Publicly listed on stock exchange	France
Nicox S.A.	Pharma	21.4	Publicly listed on stock exchange	France
Lophius Biosciences GmbH	Biotechnology / R&D Services	4.3	Private / independent	Germany
Atrys Health	Biotechnology / R&D Services	4.5	Private / independent	Spain
InflaRx GmbH	Biotechnology - Therapeutics and Diagnostics	31.0	Private / independent	Germany
Biocartis NV	Biotechnology - Therapeutics and Diagnostics	55.0	Publicly listed on stock exchange	Belgium
Mobidiag Ltd.	Biotechnology - Therapeutics and Diagnostics	13.6	Private / independent	Finland
Poxel SA	Biotechnology - Therapeutics and Diagnostics	26.5	Publicly listed on stock exchange	France
SymCel Sverige AB	Biotechnology / R&D Services	0.0	Private / independent	Sweden
Pharnext SAS	Biotechnology - Therapeutics and Diagnostics	30.9	Private / independent	France
GenSight Biologics SA	Biotechnology - Therapeutics and Diagnostics	40.0	Publicly listed on stock exchange	France

CryoTherapeutics GmbH	Medical Technology	5.2	Private / independent	Germany
Nyxoah	Medical Technology	18.1	Private / independent	Belgium
Anaxomics Biotech SL	Biotechnology / R&D Services	0.1	Private / independent	Spain
Andrés Pinaluba S.A.	Biotechnology - other	0.1	Private / independent	Spain
Aniling	Biotechnology / R&D Services	0.2	Private / independent	Spain
Aromics	Biotechnology / R&D Services	0.1	Private / independent	Spain
BCN Peptides	Biotechnology / R&D Services	0.2	Private / independent	Spain
HIPRA	Biotechnology - other	0.4	Private / independent	Spain
Intelligent Pharma	Biotechnology / R&D Services	0.1	Private / independent	Spain
Minoryx Therapeutics	Biotechnology - Therapeutics and Diagnostics	0.2	Private / independent	Spain
Nanomol	Biotechnology / R&D Services	0.1	Subsidiary	Spain
NightBalance B.V.	Medical Technology	12.5	Private / independent	Netherlands

UD: undisclosed

Source: Biotechgate.com



About this summary

The Life Sciences Financing Summary is published on a bi-monthly basis by Venture Valuation and Fit for Health 2.0 and can be downloaded for free either from our newsletter or from the website <http://www.fitforhealth.eu/>

The data used for this summary is taken from Venture Valuation's global Biotech and life science database Biotechgate. Biotechgate is a popular source for life sciences company and licensing deals information. If you are interested in learning more, please do not hesitate to contact us and to apply for a trial.

[Click here to learn more about Biotechgate »](#)

Venture Valuation
Kasernenstrasse 11
8004 Zurich
Switzerland

Phone: +41 (43) 321 86 60

Web: www.venturevaluation.com

Copyright © 2016 Venture Valuation VV Ltd. All rights reserved. This report is provided for information purposes only. All information regarding financing rounds, deal summaries and merger and acquisition transactions was obtained from company websites or industry newsletters including Fiercebitech, OnBioVC, and SECA. The above information can also be accessed on the Biotechgate website. All graphical information was provided via Biotechgate. While the information contained herein has been obtained from sources deemed reliable, Venture Valuation VV Ltd makes no guarantees that it is accurate, complete, timely, or sequential. For more information about Biotech companies, including deal, licensing and financing round details, please visit the Biotechgate website at www.biotechgate.com

Email: info@venturevaluation.com